Pasithea Therapeutics Reports Q1 2026 Financial Results with $2.87M Net Loss

Pasithea Therapeutics Corp. reported its financial results for the first quarter of 2026, revealing a net loss of $2.87 million, a 19.5% improvement compared to a net loss of $3.56 million in the same period of 2025. The company’s total revenue for the quarter was not specified, but it noted significant increases in research and development expenses, which rose by 70.1% to $2.94 million, primarily due to heightened clinical trial and regulatory costs associated with its lead product candidate, PAS-004. General and administrative expenses slightly decreased by 0.8% to $1.93 million, reflecting a reduction in various operational costs.

In terms of financial position, Pasithea's total assets decreased to approximately $56.35 million as of March 31, 2026, down from $60.24 million at the end of 2025. The company’s cash and cash equivalents also fell to $50.4 million from $55.2 million, indicating a cash burn rate that necessitates ongoing capital raising efforts. Current liabilities significantly decreased to $1.49 million from $4.97 million, largely due to the reclassification of certain warrant liabilities to equity. This shift reflects a strategic move to strengthen the balance sheet and improve liquidity.

Operationally, Pasithea is advancing its clinical trials for PAS-004, a next-generation MEK inhibitor, which is currently undergoing a Phase 1 multicenter trial for patients with MAPK pathway-driven advanced tumors. The company has completed initial cohorts and is exploring higher dose levels with a tablet formulation. Additionally, a Phase 1/1b trial for neurofibromatosis type 1 patients is ongoing across multiple sites in the U.S., Australia, and South Korea. The company aims to seek FDA approval for PAS-004 in treating symptomatic plexiform neurofibromas in both adult and pediatric populations.

Looking ahead, Pasithea anticipates continued increases in research and development expenditures as it progresses through clinical trials and prepares for potential commercialization. The company emphasized the need for additional funding through equity or debt sales to support its operational and developmental plans. Management expressed confidence that its current cash reserves would sustain operations for at least the next twelve months, although they acknowledged the necessity of securing further capital to meet long-term objectives.